Viatris Inc. - Common Stock (NQ:VTRS)

17.54 -0.08 (-0.45%)

Delayed Quote Updated: 4:00 PM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Viatris Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

22 23 Next >

Stay informed with the top movers within the S&P500 index on Tuesday. ↗

March 18, 2025

Stay informed about the performance of the S&P500 index one hour before the close of the markets on Tuesday. Uncover the top gainers and losers in today's session for valuable insights.

Via Chartmill

Uncover the latest developments among S&P500 stocks in today's session. ↗

March 18, 2025

Stay updated with the movements of the S&P500 index in the middle of the day on Tuesday. Discover which stocks are leading as top gainers and losers in today's session.

Via Chartmill

Q4 Earnings Roundup: Elanco (NYSE:ELAN) And The Rest Of The Pharmaceuticals Segment

March 18, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how pharmaceuticals stocks fared in Q4, starting with Elanco...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Forecasting The Future: 4 Analyst Projections For Viatris ↗

March 05, 2025

Via Benzinga

Earnings Scheduled For February 27, 2025 ↗

February 27, 2025

Via Benzinga

Viatris Inc. Announcement: If You Have Suffered Losses in Viatris Inc. (NASDAQ: VTRS), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

March 16, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris

March 15, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

Rosen Law Firm Encourages Viatris Inc. Investors to Inquire About Securities Class Action Investigation – VTRS

March 14, 2025

From The Rosen Law Firm, P.A.

Via Business Wire

Q4 Earnings Highs And Lows: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs The Rest Of The Generic Pharmaceuticals Stocks

March 13, 2025

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at generic pharmaceuticals stocks, starting...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Securities Fraud Investigation Into Viatris Inc. (VTRS) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

March 12, 2025

From Glancy Prongay & Murray LLP

Via Business Wire

Viatris Inc. (VTRS) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

March 12, 2025

From Law Offices of Howard G. Smith

Via Business Wire

Securities Fraud Investigation Into Viatris Inc. (VTRS) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

March 11, 2025

From The Law Offices of Frank R. Cruz

Via Business Wire

1 Healthcare Stock to Target This Week and 2 to Turn Down

March 11, 2025

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the...

Via StockStory

Topics Stocks

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris

March 09, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris

March 05, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers

March 05, 2025

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Explore the top gainers and losers within the S&P500 index in today's session. ↗

March 03, 2025

Stay informed about the performance of the S&P500 index in the middle of the day on Monday. Uncover the top gainers and losers in today's session for valuable insights.

Via Chartmill

Tesla, Palantir And MicroStrategy Are Among Top 12 Large-Cap Losers Last Week (Feb 24-Feb 28): Are The Others In Your Portfolio? ↗

March 02, 2025

12 large-cap stocks plummeted last week due to negative financial reports. These include SMCI, APP, CART, NTAP, PSTG, DUOL, VTRS, SRE, PLTR, TCOM, MSTR, and TSLA.

Via Benzinga

Stay informed with the top movers within the S&P500 index on Thursday. ↗

February 27, 2025

Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Thursday as we examine the latest happenings in today's session.

Via Chartmill

Why Viatris (VTRS) Shares Are Falling Today

February 27, 2025

Shares of medication company Viatris (NASDAQ:VTRS) fell 16.9% in the morning session after the company reported disappointing fourth-quarter 2024 results, with sales, earnings, and operating income all...

Via StockStory

What's going on in today's session: S&P500 most active stocks ↗

February 27, 2025

Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Thursday. Discover the stocks that are generating the highest...

Via Chartmill

Viatris Stock Tumbles On Q4 Earnings Miss, FDA Warning Clouds 2025 Outlook ↗

February 27, 2025

Viatris missed Q4 estimates with an 8% revenue decline. 2025 guidance falls short as FDA import alert hits sales. Share repurchases prioritized.

Via Benzinga

Topics Earnings

Discover which S&P500 stocks are making waves on Thursday. ↗

February 27, 2025

Let's delve into the developments on the US markets in the middle of the day on Thursday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.

Via Chartmill

Gapping S&P500 stocks in Thursday's session ↗

February 27, 2025

Stay updated with the S&P500 gap up and gap down stocks on Thursday. Get a glimpse of the market's movement during today's session.

Via Chartmill

Viatris Misses Estimates, Cash Flow Up ↗

February 27, 2025

Viatris reported mixed results for Q4 2024, missing revenue and EPS expectations, despite noteworthy debt reduction and portfolio adjustments.

Via The Motley Fool

Get insights into the top movers in the S&P500 index of Thursday's pre-market session. ↗

February 27, 2025

Curious about the S&P500 stocks that are showing activity before the opening bell on Thursday?

Via Chartmill

Earnings To Watch: Amneal (AMRX) Reports Q4 Results Tomorrow

February 27, 2025

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting results tomorrow before market hours. Here’s what investors should know.

Via StockStory

Viatris (NASDAQ:VTRS) Misses Q4 Revenue Estimates, Stock Drops

February 27, 2025

Medication company Viatris (NASDAQ:VTRS) fell short of the market’s revenue expectations in Q4 CY2024, with sales falling 8.1% year on year to $3.53 billion. The company’s full-year revenue guidance of...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Viatris Earnings: What To Look For From VTRS

February 26, 2025

Medication company Viatris (NASDAQ:VTRS) will be reporting results tomorrow before market open. Here’s what to expect.

Via StockStory

Q3 Earnings Outperformers: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Stocks

February 21, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q3, starting with...

Via StockStory

Topics Artificial Intelligence Intellectual Property

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

22 23 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.